Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 17/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388276 | 0.93 | OPRM1 (0.58) | OPRM1OPRD1OPRK1HRH3 | |
| SCHEMBL388303 | 0.88 | OPRM1 (0.58) | OPRM1OPRD1OPRK1HRH3 | |
| SCHEMBL388553 | 0.88 | OPRM1 (0.55) | OPRM1OPRD1OPRK1HRH3 | |
| SCHEMBL390458 | 0.86 | OPRM1 (0.56) | OPRM1OPRD1OPRK1HRH3 | |
| SCHEMBL388295 | 0.85 | OPRM1 (0.59) | OPRM1OPRD1OPRK1HRH3 | |
| SCHEMBL385590 | 0.83 | OPRM1 (0.57) | OPRM1OPRD1OPRK1HRH3 | |
| SCHEMBL383035 | 0.82 | OPRM1 (0.53) | OPRM1OPRD1OPRK1HRH3 | |
| SCHEMBL387365 | 0.82 | OPRM1 (0.49) | OPRM1OPRD1OPRK1HRH3 | |
| SCHEMBL388366 | 0.81 | OPRM1 (0.59) | OPRM1OPRD1OPRK1HRH3 | |
| SCHEMBL389947 | 0.81 | HRH3 (0.51) | OPRM1OPRD1OPRK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | claimed |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PEDREGAL-TERCERO CONCEPCION | 2009-01-22 | — | — | US | claimed |
| EP-1613597-B1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2007-11-07 | — | — | EP | claimed |
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-09-14 | — | — | US | claimed |
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PEDREGAL-TERCERO CONCEPCION | 2009-01-22 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1613597-B1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRD1 5/4885OPRK1 3/4885 |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.